1152311-62-0
- Product Name：Tezacaftor
- Molecular Formula：C26H27F3N2O6
- Purity：99%
- Molecular Weight：520.505
Product Details;
CasNo： 1152311-62-0
Molecular Formula： C26H27F3N2O6
Cost-effective and customizable Tezacaftor 1152311-62-0 in stock
- Molecular Formula:C26H27F3N2O6
- Molecular Weight:520.505
- Boiling Point:610.8±55.0 °C(Predicted)
- PKA:13.99±0.20(Predicted)
- PSA：113.18000
- Density:1.49±0.1 g/cm3(Predicted)
- LogP:3.46830
VX-661(Cas 1152311-62-0) Usage
|
Biochem/physiol Actions |
VX-661 is another cystic fibrosis transmembrane conductance regulator (CFTR) corrector in development for the treatment of cystic fibrosis. |
|
in vitro |
VX-661, is CFTR modulator that is potentially useful for treatment of cystic fibrosis. VX-661 corrects F508del-CFTR trafficking and increases F508del-CFTR protein activity in vitro. |
|
references |
[1] s. donaldson, j. pilewski, m. griese, q. dong, p.-s. lee, for the vx11–661-101 study group. ws7.3 vx-661, an investigational cftr corrector, in combination with ivacaftor, a cftr potentiator, in patients with cf and homozygous for the f508del-cftr mutation: interim analysis. journal of cystic fibrosis, volume 12, supplement 1, june 2013, page s14 |
|
Definition |
VX-661 is an investigational compound that promotes the maturation of delta F508 mutants of the cystic fibrosis transmembrane conductance regulator (CFTR). Delta F508 CFTR represents a class of CFTR mutation that is characterized by impaired processing of misfolded CFTR proteins and reduced accumulation of the protein at the cell surface. VX-661 is intended to facilitate trafficking of CFTR to the epithelial cell membrane. It may be combined with the CFTR potentiator ivacaftor (Item No. 15145) to stimulate both CFTR accumulation and opening at the apical epithelial surface. |
InChI:InChI=1S/C26H27F3N2O6/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35)/t16-/m1/s1
1152311-62-0 Relevant articles
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
-
, (2021/04/21)
The present invention features compositi...
NOVEL CRYSTALLINE FORM OF 1-(2,2-DIFLUORO-2H-1,3BENZO DIOXOL-5-YL)-N-{1-[(2R)-2,3-DIHYDROXYPROPYL]-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL}CYCLOPROPANE-1-CARBOXAMIDE AND ITS PROCESS FOR THE PREPARATION THEREOF
-
, (2021/07/17)
The present application relates to a nov...
NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR
-
, (2021/08/14)
The present invention generally relates ...
SOLID FORMS OF TEZACAFTOR, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
-
Page/Page column 34, (2021/05/21)
The present invention relates to solid f...
1152311-62-0 Process route
-
-
C33H33F3N2O6
-
![(R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide](/upload/2026/7/fe310920-fd2d-45ba-9238-1005fb677f67.png)
-
1152311-62-0
(R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
| Conditions | Yield |
|---|---|
|
With
palladium 10% on activated carbon; hydrogen;
In
methanol;
at 30 - 35 ℃;
for 4h;
under 1500.15 - 2250.23 Torr;
|
98.2% |
-
-
C34H35F3N2O7
-
-
1152311-62-0
(R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
| Conditions | Yield |
|---|---|
|
With
hydrogen;
In
acetonitrile;
at 40 - 45 ℃;
for 4h;
under 2250.23 - 3000.3 Torr;
|
96.1% |
1152311-62-0 Upstream products
-
1152311-90-4
(R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
-
2369-13-3
3-fluoro-4-nitroaniline
-
33070-32-5
5-bromo-2,2-difluoro-2H-1,3-benzodioxole
-
656-46-2
2,2-difluoro-1,3-benzodioxole-5-carboxylic acid
Relevant Products
-
OrforglipronCAS：2212020-52-3
-
Pal-Glu(Osu)-OHCAS：294855-91-7
-
Fmoc-L-3-Pal-OHCAS：175453-07-3
